Sorafenib Inhibits Renal Fibrosis Induced by Unilateral Ureteral Obstruction via Inhibition of Macrophage Infiltration

Cellular Physiology and Biochemistry

Volumn 39, Issue 5, 2016, Pages 1837-1849

  Ma, Wenting ^a   Tao, Le ^a   Wang, Xuefei ^a   Liu, Qinyi ^a   Zhang, Wei ^b   Li, Qiuying ^b   He, Chunfeng ^b   Xue, Dongying ^a   Zhang, Jie ^a   Liu, Cheng ^b  

^a Department of Infectious Disease ^*  (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Macrophage; Renal fibrosis; Sorafenib

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CHLORDANE; MONOCYTE CHEMOTACTIC PROTEIN 1; SORAFENIB; TRANSFORMING GROWTH FACTOR BETA1; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; CCL2 PROTEIN, MOUSE; CD68 PROTEIN, MOUSE; CXCL11 CHEMOKINE; CXCL11 PROTEIN, MOUSE; CXCR3 PROTEIN, MOUSE; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; MESSENGER RNA; NICOTINAMIDE; TGFB1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CELL INFILTRATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; EPITHELIUM CELL; HISTOPATHOLOGY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MACROPHAGE MIGRATION INHIBITION; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; OBSTRUCTION-INDUCED RENAL FIBROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TREATMENT OUTCOME; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL ADHESION; CELL MOTION; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; KIDNEY TUBULE; MACROPHAGE; PATHOLOGY; SIGNAL TRANSDUCTION; URETER; URETERAL OBSTRUCTION;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC AGENTS; CELL ADHESION; CELL MOVEMENT; CHEMOKINE CCL2; CHEMOKINE CXCL11; DISEASE MODELS, ANIMAL; FIBROSIS; GENE EXPRESSION REGULATION; HUMANS; KIDNEY TUBULES; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MYOFIBROBLASTS; NIACINAMIDE; PHENYLUREA COMPOUNDS; RECEPTORS, CXCR3; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1; URETER; URETERAL OBSTRUCTION;

EID: 84991826485     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000447883     Document Type: Article

References (32)

1. Sakuraya K, Endo A, Someya T, Hirano D, Murano Y, Fujinaga S, Ohtomo Y, Shimizu T: The synergistic effect of mizoribine and a direct renin inhibitor, aliskiren, on unilateral ureteral obstruction induced renal fibrosis in rats. J Urol 2014;191:1139-1146.
2. Xiao H, Si L, Liu W, Li N, Meng G, Yang N, Chen X, Zhou Y, Shen H: The effects of adenosine A2A receptor knockout on renal interstitial fibrosis in a mouse model of unilateral ureteral obstruction. Acta Histochem 2013;115:315-319.
3. Kui Tan T, Zheng G, Hsu T, Ra Lee S, Zhang J, Zhao Y, Tian X, Wang Y, Min Wang Y, Cao Q, Wang Y, Lee VW, Wang C, Zheng D, Alexander SI, Thompson E, Harris DCH: Matrix metalloproteinase-9 of tubular and macrophage origin contributes to the pathogenesis of renal fibrosis via macrophage recruitment through osteopontin cleavage. Lab Invest 2013;93:434-449.
4. Tan TK, Zheng G, Hsu T, Wang Y, Lee VWS, Tian X, Wang Y, Cao Q, Wang Y, Harris DCH: Macrophage matrix metalloproteinase-9 mediates Epithelial-Mesenchymal transition in vitro in murine renal tubular cells. Am I Pathol 2010;176:1256-1270.
5. Choi DE, Jeong JY, Lim BJ, Chang Y, Na K, Shin Y, Lee KW: Aliskiren ameliorates renal inflammation and fibrosis induced by unilateral ureteral obstruction in mice. J Urol 2011;186:694-701.
6. Schiitte K, Zimmermann L, Bornschein J, Csepregi A, Riihl R, Ricke J, Malfertheiner P: Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis. Digestion 2011;83:275-282.
7. Pinter M, Sieghart W, Reisegger M, Wrba F, Peck-Radosavljevic M: Sorafenib in unresectable intrahepatic cholangiocellular carcinoma: A case report. Wien Klin Wochenschr 2011;123:61-64.
8. Hennenberg M, Trebicka J, Stark C, Kohistani AZ, Heller J, Sauerbruch T: Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. Br J Pharmacol 2009;157:258-270.
9. Hsu C, Shen Y, Lin Z, Chen P, Shao Y, Ding Y, Hsu C, Cheng A: Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol 2010;53:126-131.
10. Hong F, Chou H, Fiel MI, Friedman SL: Antifibrotic activity of sorafenib in experimental hepatic fibrosis: Refinement of inhibitory targets, dosing, and window of efficacy in vivo. Dig Dis Sci 2012;58:257-264.
11. Wang Y, Gao J, Zhang D, Zhang J, Ma J, Jiang H: New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J Hepatol 2010;53:132-144.
12. Jia L, Ma X, Gui B, Ge H, Wang L, Ou Y, Tian L, Chen Z, Duan Z, Han J, Fu R: Sorafenib ameliorates renal fibrosis through inhibition of TGF-β-Induced Epithelial-Mesenchymal transition. PLos One 2015;10:ell7757.
13. Liu Y, Wang Y, Zhuang F, Xian S, Fang J, Su W, Zhang W: Immunosuppression effects of bone marrow mesenchymal stem cells on renal interstitial injury in rats with unilateral ureteral obstruction. Cell Immunol 2012;276:144-152.
14. Ikezumi Y, Suzuki T, Hayafuji S, Okubo S, Nikolic-Paterson DJ, Kawachi H, Shimizu F, Uchiyama M: The sialoadhesin (CD169) expressing a macrophage subset in human proliferative glomerulonephritis. Nephrol Dial Transplant 2005;20:2704-2713.
15. Sung WJ, Kim K, Kim Y, Chang Y, Lee IH, Park K: Antifibrotic effect of synthetic Smad/Spl chimeric decoy oligodeoxynucleotide through the regulation of epithelial mesenchymal transition in unilateral ureteral obstruction model of mice. Exp Mol Pathol 2013;95:136-143.
16. Nishida M, Hamaoka K: Macrophage phenotype and renal fibrosis in obstructive nephropathy. Nephron Exp Nephrol 2008;110:e31-e36.
17. Zimmerman DL, Zimpelmann J, Xiao F, Gutsol A, Touyz R, Burns KD: The effect of angiotensin-(l-7) in mouse unilateral ureteral obstruction. Am J Pathol 2015;185:729-740.
18. Hatano M, Sasaki S, Ohata S, Shiratsuchi Y, Yamazaki T, Nagata K, Kobayashi Y: Effects of Kupffer cell-depletion on Concanavalin A-induced hepatitis. Cell Immunol 2008;251:25-30.
19. Torraca V, Cui C, Boland R, Bebelman JP, van der Sar AM, Smit MJ, Siderius M, Spaink HP, Meijer AH: The CXCR3/CXCL11 signaling axis mediates macrophage recruitment and dissemination of mycobacterial infection. Dis Model Mech 2015;8:253-269
20. Tsutsumi T, Adachi M, Nikawadori M, Morishige J, Tokumura A: Presence of bioactive lysophosphatidic acid in renal effluent of rats with unilateral ureteral obstruction. Life Sci 2011;89:195-203.
21. Uchida Y, Miyajima A, Kikuchi E, Kozakai N, Kosaka T, Ieda M, Fukuda K, Ohigashi T, Oya M: Renal damage inhibited in mice lacking angiotensinogen gene subjected to unilateral ureteral obstruction. Urology 2009;74:938-943.
22. Tieu BC, Lee C, Sun H, Lejeune W, Recinos A, Ju X, Spratt H, Guo D, Milewicz D, Tilton RG, Brasier AR: An adventitial IL-6/MCP1 amplification loop accelerates macrophage-mediated vascular inflammation leading to aortic dissection in mice. J Clin Invest 2009;119:3637-3651.
23. Burdick MD, Murray LA, Keane MP, Xue YY, Zisman DA, Belperio JA, Strieter RM: CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. Am J Resp Crit Care 2005;171:261-268.
24. Chen Y, Huang Y, Reiberger T, Duyverman AM, Huang P, Samuel R, Hiddingh L, Roberge S, Koppel C, Lauwers GY, Zhu AX, Jain RK, Duda DG: Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology 2014;59:1435-1447.
25. Zeng J, Dou Y, Guo J, Wu X, Dai Y: Paeoniflorin of Paeonia lactiflora prevents renal interstitial fibrosis induced by unilateral ureteral obstruction in mice. Phytomedicine 2013;20:753-759.
26. Ito K, Yoshii H, Asano T, Seta K, Mizuguchi Y, Yamanaka M, Tokonabe S, Hayakawa M, Asano T: Adrenomedullin increases renal nitric oxide production and ameliorates renal injury in mice with unilateral ureteral obstruction. J Urol 2010;183:1630-1635.
27. Chen Y, Zhang X, Bai J, Gai L, Ye X, Zhang L, Xu Q, Zhang Y, Xu L, Li H, Ding X: Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: Potential roles in the inhibition of epithelial-mesenchymal transition and fibroblast activation. Cell Death and Dis 2013;4:e665. doi: 10.1038/cddis.2013.154
28. Ali BH, Al Zaabi M, Adham SA, Yasin J, Nemmar A, Schupp N: Therapeutic effect of chrysin on Adenine-Induced chronic kidney disease in rats. Cell Physiol Biochem 2016;38:248-257.
29. Wang D, Guan M, Zheng Z, Li W, Lyv F, Pang R, Xue Y: Transcription factor egrl is involved in high Glucose-Induced proliferation and fibrosis in rat glomerular mesangial cells. Cell Physiol Biochem 2016;36:2093-2107.
30. Feger M, Alesutan I, Castor T, Mia S, Musculus K, Voelkl J, Lang F: Inhibitory Effect of NH4C1 Treatment on Renal Tgffil Signaling Following Unilateral Ureteral Obstruction. Cell Physiol Biochem 2015;37:955-964.
31. Garc A-S Nchez 0, Sancho-Mart Nez SM, L Pez-Novoa JM, L Pez-Hern Ndez FJ: Activation of the ALK-5 Pathway is not per se Sufficient for the Antiproliferative Effect of TGF-β on Renal Tubule Epithelial Cells. Cell Physiol Biochem 2015;37:1231-1239.
32. Su T, Shiau C, Jao P, Liu C, Liu C, Tai W, Jeng Y, Yang H, Tseng T, Huang H, Cheng H, Chen P, Chen K, Kao I, Chen D: Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition. Proc Natl Acad SciU S A 2015;112:7243-7248.